argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Employees

1,599

Sector

Biotechnology & Medical Research

Calendar

07-31 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
25-06-23	466.00 €	-1.08%	119,159
25-06-20	471.10 €	-0.44%	219,452
25-06-19	473.20 €	+0.08%	24,799
25-06-18	472.80 €	0.00%	56,212
25-06-17	472.80 €	-2.13%	80,064

Real-time Euronext Bruxelles, June 23, 2025 at 10:56 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

471.10EUR

Average target price

666.26EUR

Spread / Average Target

+41.43%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Bruxelles Other stock markets 11:35:43 2025-06-23 EDT			After hours 15:59:59
466.00 ^EUR	-1.08%		468.20	+0.47%

11:59pm	Argenx Obtains Approval in EU for Monotherapy for Rare Autoimmune Disease	MT
06-20	Sector Update: Health Care Stocks Softer in Afternoon Trading	MT

Capitalization	28.77B 33.16B 27.1B 24.62B 45.55B 2,872B 51.32B 321B 123B 1,316B 124B 122B 4,837B	P/E ratio 2025 *	47.4x	P/E ratio 2026 *	27.4x
Enterprise value	25.89B 29.85B 24.39B 22.16B 40.99B 2,585B 46.19B 289B 111B 1,184B 112B 110B 4,353B	EV / Sales 2025 *	8.1x	EV / Sales 2026 *	5.96x
Free-Float	99.23%	Yield 2025 *	-	Yield 2026 *	-

Argenx Obtains Approval in EU for Monotherapy for Rare Autoimmune Disease	11:59pm	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	06-20	MT
Argenx SE Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-20	CI
Argenx Receives European Commission Approval for Monotherapy to Treat Neuromuscular Disorder	06-20	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06-16	MT
Argenx Says Vyvgart Improved Muscle Strength in Phase 2 Myositis Trial	06-11	MT
Argenx SE Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease	06-11	CI
Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren'S Disease	06-10	RE
Argenx SE Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08:40 AM	06-10
Scholar Rock Holding Corporation Announces Appointment of Rebecca Mcleod as Chief Brand Officer	06-02	CI
European Equities Close Lower in Wednesday Trading; French GDP Edges Higher	05-28	MT
Argenx Set to See Further Growth Due to Vyvgart Momentum, Pipeline Expansion, Wedbush Says	05-28	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05-21	MT

Baird Upgrades argenx to Outperform From Neutral, Price Target is $680	05-13	MT
Bernstein Upgrades argenx to Outperform, Boosts PT	03-17	MT
Wedbush Raises Argenx's Price Target to $665 From $655, Maintains Outperform Rating	12-27	MT
Oppenheimer Adjusts argenx SE ADR Price Target to $675 From $646, Maintains Outperform Rating	11-21	MT
Morgan Stanley Raises Price Target on argenx to $675 From $580, Keeps Overweight Rating	11-18	MT

argenx SE Stock

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Valuation: argenx SE

Chart: argenx SE

Latest news: argenx SE

Last Transcript: argenx SE

Analysts' recommendations: argenx SE

Press Releases: argenx SE

News in other languages: argenx SE

Quotes and Performance

Course Extremes

Managers and Directors: argenx SE

ETFs: argenx SE

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-20	GL
Argenx : argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-19	PU
Argenx : argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	06-11	PU
Argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	06-10	GL
Argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	06-10	AQ

Washington cogne d'abord et discute ensuite	03:03am
Bourse : Kering sort de l'Euro Stoxx 50, Filosa débarque chez Stellantis, Carmat au bord du gouffre	02:46am
Argenx krijgt Europese goedkeuring voor Vyvgart als injectie tegen CIDP	01:30am
FTSE MIB, CAC40, DAX, SMI: 9 indici, 9 climi diversi	06-20
Deux semaines de réflexion	06-20

1 day	-0.55%
1 week	-3.02%
Current month	-7.48%
1 month	-8.96%
3 months	-17.08%
6 months	-21.31%
Current year	-21.92%

1 week	467.1	483.8
1 month	467.1	527.8
Current year	466.5	658
1 year	394.2	658
3 years	271	658
5 years	180.1	658
10 years	8.46	658

Manager	Title	Age	Since
Tim van Hauwermeiren CEO	Chief Executive Officer	53	2008-07-14
Karl Gubitz DFI	Director of Finance/CFO	55	2021-05-31
Filip Borgions CTO	Chief Tech/Sci/R&D Officer	-	2014-12-31

Director	Title	Age	Since
Tim van Hauwermeiren BRD	Director/Board Member	53	2014-06-30
Peter K. M. Verhaeghe CHM	Chairman	67	2008-10-14
Joseph deBethizy BRD	Director/Board Member	75	2015-05-12

Name	Weight	AuM	1st Jan change
HAN-GINS TECH MEGATREND EQUAL WEIGHT UCITS ETF - USD	0.93%	80 M€	-3.79%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.46%	21 M€	-0.24%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARGENX SE	-0.55%	-3.02%	+15.54%	+37.79%	33.16B
REGENERON PHARMACEUTICALS, INC.	+0.83%	-1.93%	-51.82%	-15.61%	53.86B
BIONTECH SE	-3.38%	-3.04%	+19.04%	-22.07%	26.23B
WUXI APPTEC CO., LTD.	0.00%	-4.39%	+61.20%	-30.38%	26.05B
INSMED INCORPORATED	+1.01%	+2.08%	+51.54%	+422.42%	19.5B
SUMMIT THERAPEUTICS INC.	-1.73%	+1.65%	+153.50%	+1,694.69%	15.27B
GENMAB A/S	-1.85%	-8.17%	-24.99%	-37.40%	13.11B
WUXI BIOLOGICS (CAYMAN) INC.	+1.66%	-7.55%	+106.93%	-64.97%	12.49B
EXELIXIS, INC.	+11.02%	+8.62%	+103.18%	+112.61%	11.01B
AKESO, INC.	+4.27%	-3.69%	+149.21%	+293.39%	10.44B
Average	+1.14%	-3.25%	+58.33%	+239.05%	22.11B
Weighted average by Cap.	+0.43%	-3.01%	+31.06%	+163.52%

	2025 *	2026 *
Net sales	3.19B 3.68B 3.01B 2.73B 5.06B 319B 5.7B 35.63B 13.64B 146B 13.82B 13.52B 537B	4.15B 4.79B 3.91B 3.56B 6.58B 415B 7.41B 46.34B 17.73B 190B 17.97B 17.59B 699B
Net income	729M 840M 686M 624M 1.15B 72.75B 1.3B 8.13B 3.11B 33.33B 3.15B 3.08B 123B	1.23B 1.41B 1.15B 1.05B 1.94B 122B 2.19B 13.67B 5.23B 56.05B 5.3B 5.19B 206B
Net Debt	-2.88B -3.32B -2.71B -2.46B -4.56B -287B -5.13B -32.09B -12.28B -132B -12.45B -12.18B -484B	-4B -4.61B -3.77B -3.42B -6.34B -400B -7.14B -44.64B -17.08B -183B -17.31B -16.94B -673B